ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer
-
Published:2023-03-30
Issue:7
Volume:24
Page:6519
-
ISSN:1422-0067
-
Container-title:International Journal of Molecular Sciences
-
language:en
-
Short-container-title:IJMS
Author:
Montanaro Manuela1, Agostini Massimiliano1ORCID, Anemona Lucia1ORCID, Bonanno Elena1, Servadei Francesca1ORCID, Finazzi Agrò Enrico2, Asimakopoulos Anastasios D.2ORCID, Ganini Carlo1, Cipriani Chiara13ORCID, Signoretti Marta3, Bove Pierluigi13, Rugolo Francesco1ORCID, Imperiali Benedetta1ORCID, Melino Gerry1, Mauriello Alessandro1ORCID, Scimeca Manuel145ORCID
Affiliation:
1. Department of Experimental Medicine, Tor Vergata Oncoscience Research (TOR), University of Rome Tor Vergata, 00133 Rome, Italy 2. Department of Surgical Sciences, Division of Urology, University of Rome Tor Vergata, 00133 Rome, Italy 3. San Carlo di Nancy Hospital, 00165 Rome, Italy 4. San Raffaele University, Via di Val Cannuta 247, 00166 Rome, Italy 5. Faculty of Medicine, Saint Camillus International University of Health Sciences, Via di Sant’Alessandro 8, 00131 Rome, Italy
Abstract
Prostate cancer is the most frequently diagnosed cancer and the fifth leading cause of cancer death among men in 2020. The clinical decision making for prostate cancer patients is based on the stratification of the patients according to both clinical and pathological parameters such as Gleason score and prostate-specific antigen levels. However, these tools still do not adequately predict patient outcome. The aim of this study was to investigate whether ZNF750 could have a role in better stratifying patients, identifying those with a higher risk of metastasis and with the poorest prognosis. The data reported here revealed that ZNF750 protein levels are reduced in human prostate cancer samples, and this reduction is even higher in metastatic samples. Interestingly, nuclear positivity is significantly reduced in patients with metastatic prostate cancer, regardless of both Gleason score and grade group. More importantly, the bioinformatics analysis indicates that ZNF750 expression is positively correlated with better prognosis. Overall, our findings suggest that nuclear expression of ZNF750 may be a reliable prognostic biomarker for metastatic prostate cancer, which lays the foundation for the development of new biological therapies.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference87 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021 2. Development and prevalence of castration-resistant prostate cancer subtypes;Vellky;Neoplasia,2020 3. Scimeca, M., Montanaro, M., Bonfiglio, R., Anemona, L., Agrò, E.F., Asimakopoulos, A.D., Bei, R., Manzari, V., Urbano, N., and Giacobbi, E. (2022). The ETS Homologous Factor (EHF) Represents a Useful Immunohistochemical Marker for Predicting Prostate Cancer Metastasis. Diagnostics, 12. 4. Mapelli, S.N., Albino, D., Mello-Grand, M., Shinde, D., Scimeca, M., Bonfiglio, R., Bonanno, E., Chiorino, G., Garcia-Escudero, R., and Catapano, C.V. (2020). A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers, 12. 5. Urbano, N., Scimeca, M., Crocco, A., Mauriello, A., Bonanno, E., and Schillaci, O. (2019). 18F-Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers. J. Clin. Med., 8.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|